References
- The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8) , 753–764 (2009).
- Anderson JL , HorneBD, StevensSM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22) , 2563–2570 (2007).
- Caraco Y , BlotnickS, MuszkatM. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther.83(3) , 460–470 (2008).
- Lenzini PA , GriceGR, MilliganPE et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J. Thromb. Haemost. 6(10) , 1655–1662 (2008).
- Epstein RS , MoyerTP, AubertRE et al. Warfarin genotyping reduces hospitalization rates results from the MM–WES (Medco–Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25) , 2804–2812 (2010).
- Burmester JK , BergRL, YaleSH et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet. Med. 13(6) , 509–518 (2011).
- Anderson JL , HorneBD, StevensSM et al. Randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing: CoumaGen-II. Circulation 125(16) , 1997–2005 (2012).
- Gage BF , EbyC, JohnsonJA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3) , 326–331 (2008).
- French B , JooJ, GellerNL et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11 , 108 (2010).
- Do EJ , LenziniP, EbyCS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. doi:10.1038/tpj.2011.18 (2011) (Epub ahead of print).
References
- Ansell J , HirshJ, HylekE et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(Suppl. 6) , 160S–198S (2008).
- Hirsh J , FusterV, AnsellJ et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107 , 1692–1711 (2003).
- Wadelius M , ChenLY, ErikssonN et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121 , 23–34 (2007).
- Aithal GP , DayCP, KestevenPJ et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 , 717–719 (1999).
- Rieder MJ , ReinerAP, GageBF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352 , 2285–2293 (2005).
- International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360 , 753–764 (2009).
- Dwell MD , AwadT, JohnsonJA et al. CYP4F2 genetic variant alters required warfarin dose. Blood111 , 4106–4112 (2008).
- Bejarano-Achache I , LevyL, MlynarskyL et al. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clin. Ther. 34(4) , 811–823 (2012).
- Cooper GM , JohnsonJA, LangaeeTY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112 , 1022–1027 (2008).
- Borgiani P , CiccacciC, ForteV et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics10 , 261–266 (2009).
- Pautas E , MoreauC, Gouin-ThibaultI et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87 , 57–64 (2010).
- Zhang JE , JorgensenAL, AlfirevicA et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics 19 , 781–789 (2009).
- Lee MT , ChenCH, ChouCH et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10 , 1905–1913 (2009).
- Perini JA , StruchinerCJ, Silva-AssunçãoE, Suarez-KurtzG. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Ther.87 , 417–420 (2010).
- Cavallari LH , LangaeeTY, MomaryKM et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87 , 459–464 (2010).